---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274094"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:25:49.200279+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q3 net loss $14.1M; bitopertin Phase 2 enrollment complete

## Summary
- Cash $370.5M as of Sep 30, 2023; expected to fund operations into 2026.
- Completed enrollment for BEACON (open-label) and AURORA (placebo-controlled) Phase 2 trials of bitopertin in EPP/XLP.
- Updated BEACON data including pivotal endpoint (cumulative time in sunlight) to be presented at ASH 2023.
- Initiated Phase 1 trial of DISC-3405 for PV; received FDA fast track designation.
- R&D expenses $14.4M (up from $7.9M YoY) driven by portfolio progression and headcount.

## SEC filing metadata
- accession: 0001193125-23-274094
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/0001193125-23-274094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/d594333d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274094
- JSON: https://secwatch.observer/filing/0001193125-23-274094.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274094.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $14.1 million.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss was $14.1 million
  - Result: reported results
  source text: • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/0001193125-23-274094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.